Haematologica
HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
QUICK SEARCH:   [advanced]


     

Haematologica, Vol 92, Issue 12, 1695-1698 doi:10.3324/haematol.11709
Copyright © 2007 by Ferrata Storti Foundation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Provan, D.
Right arrow Articles by Stasi, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Provan, D.
Right arrow Articles by Stasi, R.

Autoimmune Cytopenias

Activity and safety profile of low-dose rituximab for the treatment of autoimmune cytopenias in adults

Drew Provan, Tom Butler, Maria Laura Evangelista, Sergio Amadori, Adrian C. Newland, Roberto Stasi

From Department of Haematology, Bart’s & The London, Queen Mary’s School of Medicine and Dentistry, Whitechapel, London, UK (DP, TB, ACN); Department of Medical Sciences, Ospedale "Regina Apostolorum", Albano Laziale (MLE, RS); Dept. of Hematology, "Tor Vergata" University Hospital, Rome, Italy (SA)

Correspondence: Adrian Newland, Department of Haematology, The Royal London Hospital, Whitechapel, London El 2ES, UK. E-mail: a.c.newland{at}qmul.ac.uk

We conducted a retrospective analysis of 11 consecutive patients with various autoimmune cytopenias who failed to respond to conventional treatments and received a fixed-dose regimen of rituximab (100 mg weekly for 4 consecutive weeks). Sustained complete responses were achieved in 4 out of 7 patients with idiopathic thrombocytopenic purpura and in 1 patient with autoimmune pancytopenia. A partial response was observed in 1 patient with autoimmune hemolytic anemia. The immunotherapy had no effect in 1 patient with pure red cell aplasia or in 1 patient with autoimmune neutropenia. No infusion-related or delayed toxicities attributable to rituximab were experienced by any of the patients.

Key words: autoimmune disease, cytopenias, rituximab, low dose.




This article has been cited by other articles:


Home page
 haematolHome page
G. Emilia, M. Luppi, M. Morselli, F. Forghieri, L. Potenza, and G. Torelli
A possible role for low-dose cyclosporine in refractory immune thrombocytopenic purpura
Haematologica, July 1, 2008; 93(7): 1113 - 1115.
[Full Text] [PDF]

Home page
 haematolHome page
F. Zaja, M. L. Battista, M. T. Pirrotta, S. Palmieri, M. Montagna, N. Vianelli, L. Marin, M. Cavallin, M. Bocchia, M. Defina, et al.
Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura
Haematologica, June 1, 2008; 93(6): 930 - 933.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
Copyright © 2007 by the Ferrata Storti Foundation.